Concarlo Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

Concarlo Therapeutics General Information

Description

Operator of a precision-medicine oncology firm intended to bring a precision medicine approach to breast cancer management. The company focuses on increasing drug efficacy for large tumor types, like metastatic breast cancer and several orphan cancers, including ovarian and pancreatic cancer, with diagnostic evaluations for cancer patients, specifically addressing drug resistance issues, enabling medical professionals to diagnose and treat cancer effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Downstate Biotechnology Incubator, 760 Parkside Avenue
  • Brooklyn, Suite 208
  • New York, NY 11226
  • United States
+1 (917)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Downstate Biotechnology Incubator, 760 Parkside Avenue
  • Brooklyn, Suite 208
  • New York, NY 11226
  • United States
+1 (917)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Concarlo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Secondary Transaction - Private 01-Jun-2026 Completed Generating Revenue
12. Accelerator/Incubator 01-Jan-2023 Completed Generating Revenue
11. Later Stage VC Completed Generating Revenue
10. Later Stage VC 01-May-2022 Completed Generating Revenue
9. Accelerator/Incubator 01-Jan-2021 Completed Generating Revenue
8. Grant 10-Jul-2020 Completed Generating Revenue
7. Grant 10-Jul-2020 Completed Generating Revenue
6. Early Stage VC 17-Dec-2019 Completed Generating Revenue
5. Seed Round 16-Mar-2018 $7M $7.45M Completed Generating Revenue
4. Angel (individual) 23-Mar-2017 $450K $450K Completed Generating Revenue
To view Concarlo Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Concarlo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a precision-medicine oncology firm intended to bring a precision medicine approach to breast cancer manageme
Drug Discovery
New York, NY
7 As of 2023

Durham, NC
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Concarlo Therapeutics Competitors (2)

One of Concarlo Therapeutics’s 2 competitors is Incyclix Bio, a Venture Capital-Backed company based in Durham, NC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Incyclix Bio Venture Capital-Backed Durham, NC
Blueprint Medicines Formerly VC-backed Cambridge, MA
You’re viewing 2 of 2 competitors. Get the full list »

Concarlo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Concarlo Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Creative Destruction Lab Accelerator/Incubator
Springboard Enterprises Accelerator/Incubator Minority
National Institute on Drug Abuse (NIDA) Government
BioAdvance Capital (Conshohocken) Venture Capital Minority
Catalytic Impact Foundation Not-For-Profit Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Concarlo Therapeutics FAQs

  • When was Concarlo Therapeutics founded?

    Concarlo Therapeutics was founded in 2015.

  • Where is Concarlo Therapeutics headquartered?

    Concarlo Therapeutics is headquartered in New York, NY.

  • What is the size of Concarlo Therapeutics?

    Concarlo Therapeutics has 7 total employees.

  • What industry is Concarlo Therapeutics in?

    Concarlo Therapeutics’s primary industry is Drug Discovery.

  • Is Concarlo Therapeutics a private or public company?

    Concarlo Therapeutics is a Private company.

  • What is Concarlo Therapeutics’s current revenue?

    The current revenue for Concarlo Therapeutics is .

  • How much funding has Concarlo Therapeutics raised over time?

    Concarlo Therapeutics has raised $7.69M.

  • Who are Concarlo Therapeutics’s investors?

    Creative Destruction Lab, Springboard Enterprises, National Institute on Drug Abuse (NIDA), BioAdvance Capital (Conshohocken), and Catalytic Impact Foundation are 5 of 7 investors who have invested in Concarlo Therapeutics.

  • Who are Concarlo Therapeutics’s competitors?

    Incyclix Bio and Blueprint Medicines are competitors of Concarlo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process